Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. - Wikidata - wikimedia - TriplyDB

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

http://www.wikidata.org/entity/Q33715239

about

Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load Emerging cognitive enhancing drugs.Acetylcholinesterase inhibitors: a patent review (2008 - present).Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management.Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.Two galantamine titration regimens in patients switched from donepezil.Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents

P2860

Q24235324-278F99FE-9247-41F1-8955-3F0162EDFBCE Q33596451-CF43CBC2-C684-471A-93B1-A9BE8FFD535A Q35428213-97B8B3AF-A00E-48B3-981C-9D5521943640 Q36273566-15FC771A-0C08-4316-A700-0B475512206A Q36632702-521F7237-89B1-40E4-9F9C-DEE6F338C1F0 Q37070395-164D0380-5B42-4149-A2D5-648D834686A0 Q37158584-E5889BE2-9B91-4FFF-BDBE-281356C04EE3 Q37601479-2C931294-8F38-4B9D-9992-C3ADBCC712E0 Q38024391-81EBE665-C3ED-4C6C-A480-16E85FDF8425 Q38208461-21494280-9B99-4B5D-8199-B0B34CC87A3C Q38247181-94A0EEDE-BB8D-4111-ACBD-B8BC2A922E0F Q38289739-78B8B2B8-B7C7-4379-A89A-36340E79BC79 Q38350602-0BFC2905-FD4D-4E3C-8FAB-65398F629E59 Q38899961-EA95A023-CBAE-45C1-87CA-4636B19A3CB7 Q50597460-3AAA3471-0C7E-4F74-8D8B-A72B9FB93908 Q50612791-0E96F48E-E464-46B5-927F-16D764275930 Q50783671-55889F94-6C1C-4580-84C8-CED5AF82E53C Q51491144-C7956EDF-3456-47FA-A7ED-893AE77FD3B1 Q53313228-EFFB7FB1-AD2F-42A9-ABBB-379CB6953327 Q58794595-79806FDA-F6A8-4644-B031-1A57FF9BC0BF

P2860

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

http://www.wikidata.org/entity/Q33715239

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

@ast

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

@en

type

label

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

@ast

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

@en

prefLabel

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

@ast

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

@en

P1433

Q33715239-EEFE4D47-E690-4249-BE98-AC7E3B04E4FB

P1476

Q33715239-BF889473-DB63-4302-B010-CC221F6336C4

P2093

Q33715239-02255D24-D642-4485-9034-9EFC9CDF2707

Q33715239-07853BDE-7EE2-4E2F-A78F-1209CD5B8ADB

Q33715239-35FC1FDC-2919-4222-9BD7-40150BC90D60

Q33715239-804F7CF0-08E4-43C5-B04A-52D619C940E6

P2860

Q33715239-083A36FE-E6E0-4B86-A173-3B18ACDB17F5

Q33715239-0BBD7EF9-ED3C-4161-A100-A8AAE5880FBC

Q33715239-0DF09D89-F0C6-45F7-ABDD-8CFD80977F0D

Q33715239-0FF75208-DAD7-4871-8732-CDDDB7876018

Q33715239-18218CF9-82F4-41C5-AF3C-FEB2C7E3B24F

Q33715239-1994CB3C-1085-4711-9433-5C0890070F67

Q33715239-1BB6B6F8-C7E3-45F3-9583-C639CB059D53

Q33715239-25D6D167-8680-4010-9F6F-FE37CC8B388B

Q33715239-25EF4DDC-B71D-4899-B253-264DDBB0F992

Q33715239-2B8B9EE4-F96C-41B6-9D2C-96147E344327

P304

Q33715239-918CF943-7DB6-4F00-AB86-D66E3767DD45

P31

Q33715239-E297AA25-7725-4FB6-9B5F-ADD9C7EB2B55

P356

Q33715239-F51F673B-5ECB-41FF-B438-87EEE15C1E7C

P433

Q33715239-51B94394-9B9C-4F24-A8B0-F0F621C3E91F

P478

Q33715239-E7A3D674-DBBE-4F41-945B-958C51D4EFDD

P50

Q33715239-3060DCC1-24C1-45F4-9A4A-BB989B8DD2B5

Q33715239-4A5B4BCE-0BCF-434C-9AAA-777D20B52588

Q33715239-E7BC50B1-161F-4E9C-86CC-9348068A60BF

P577

Q33715239-0F7E2B2C-54DC-46BE-B275-0DF0504AA2AA

P5875

Q33715239-EB2FC84B-E48D-4D01-8536-54111FAB6BAF

P698

Q33715239-6A8DC433-A8DD-4323-9E04-5C37B933E7DF

P921

Q33715239-7D1D843A-C8D2-40DE-90E2-5E4BF1A1F369

P932

Q33715239-B6410B1E-A0CE-492C-B51E-C67B6C2C7381

P356

156720509787313961

P1433

Current Alzheimer Research

P1476

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

@en

P2093

Elaine Peskind

http://www.w3.org/2001/XMLSchema#string

Gina Eagle

http://www.w3.org/2001/XMLSchema#string

Malahat Mousavi

http://www.w3.org/2001/XMLSchema#string

Roger Lane

http://www.w3.org/2001/XMLSchema#string

P2860

A new and rapid colorimetric determination of acetylcholinesterase activity

Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Promoter elements and alternative splicing in the human ACHE gene

Virtues and woes of AChE alternative splicing in stress-related neuropathologies

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.

Safety of lumbar puncture procedures in patients with Alzheimer's disease.

Structural roles of acetylcholinesterase variants in biology and pathology.

Mind over immunity.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

P304

4-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/156720509787313961

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Hilkka Soininen

Taher Darreh-Shori

Agneta Nordberg

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23987366

http://www.w3.org/2001/XMLSchema#string

P698

19199870

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4046577

http://www.w3.org/2001/XMLSchema#string